Axsome Therapeutics (NASDAQ:AXSM) traded lower in the premarket on Tuesday after the company said solriamfetol, its experimental therapy for depression, failed to reach the main goal in a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback